Skip to main content

Kelsey Stephen Michael's Form 4 filing

Revolution Medicines, Inc. (RVMD) · filed Sep 15, 2026

Accession no.
0001462808-26-000007
Filed
Sep 15, 2026, 6:00 PM ET
Trade date
Sep 11, 2026
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 10 non-derivative transactions and 2 derivative transactions. Open-market sales total $18.7M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kelsey Stephen MichaelCIK 0001462808Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 11, 2026Common StockMOption exerciseAcquired+52,500$42.45+$2,228,625344,376Direct
Sep 11, 2026Common StockMOption exerciseAcquired+40,031$40.74+$1,630,862.94384,407Direct
Sep 11, 2026Common StockSSaleDisposed−800$198.55F2−$158,840.16383,607Direct
Sep 11, 2026Common StockSSaleDisposed−11,833$200.11F3−$2,367,954.88371,774Direct
Sep 11, 2026Common StockSSaleDisposed−13,368$200.78F4−$2,683,985.6358,406Direct
Sep 11, 2026Common StockSSaleDisposed−21,447$201.75F5−$4,326,947.26336,959Direct
Sep 11, 2026Common StockSSaleDisposed−18,869$203.06F6−$3,831,550.46318,090Direct
Sep 11, 2026Common StockSSaleDisposed−17,949$203.87F7−$3,659,309.3300,141Direct
Sep 11, 2026Common StockSSaleDisposed−4,995$204.84F8−$1,023,189.29295,146Direct
Sep 11, 2026Common StockSSaleDisposed−3,270$205.81F9−$672,990.53291,876Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 11, 2026Common StockMOption exerciseDisposed−52,500$42.45−$2,228,6250Direct
Sep 11, 2026Common StockMOption exerciseDisposed−128,100$40.74−$1,630,862.9488,069Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The transaction was executed in multiple trades at prices ranging from $198.35 to $198.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

The transaction was executed in multiple trades at prices ranging from $199.36 to $200.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F4

The transaction was executed in multiple trades at prices ranging from $200.36 to $201.33, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F5

The transaction was executed in multiple trades at prices ranging from $201.39 to $202.37, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F6

The transaction was executed in multiple trades at prices ranging from $202.41 to $203.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F7

The transaction was executed in multiple trades at prices ranging from $203.45 to $204.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F8

The transaction was executed in multiple trades at prices ranging from $204.46 to $205.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F9

The transaction was executed in multiple trades at prices ranging from $205.57 to $206.05, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Remarks

Senior Advisor to the Chief Executive Officer

Read the full filing on SEC EDGAR (opens in a new tab)